Transrectal Ultrasound-Guided Prostate Brachytherapy

  • John Sylvester
  • John Blasko
  • Peter Grimm


The most common solid malignancy in men, prostate cancer is now being diagnosed, in most men, in the very earliest stages, in the United States (1). This surge in earlier-stage diagnosis is the result, in large part, of the introduction and increased use of the prostate-specific antigen (PSA) blood test (2). Traditional therapeutic options of radical prostatectomy and external beam radiation therapy have come under more scrutiny because PSA tests in follow-up reveal disease control rates have been found to be lower than previously thought (3–6). Neither radical prostatectomy nor external beam radiation therapy (EBRT) appear to result in superior cancer control, vs each other, when major pretreatment prognostic variables are taken into consideration (7–11). Moreover, patient-reported toxicity rates have been found to be considerably higher than the previous physician-reported rates (12).


Prostate Cancer Radical Prostatectomy Localize Prostate Cancer Memorial Sloan Kettering Cancer Center Prostate Brachytherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974–1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CACancer J Clin 1993;4:83–91.Google Scholar
  2. 2.
    Garfinkel, L, , Mushinski, M, Cancer incidence, mortality and survival: trends in four leading sites. Stat Bull Metrop Insur Co1994;75:19–27.Google Scholar
  3. 3.
    Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team [see comments]. JAMA1993;269:2650–2658.PubMedGoogle Scholar
  4. 4.
    Talcott JA, Rieker P, Propert K, et. al. Complications of treatment for early prostate cancer: a prospective, multi-insitutional outcomes study [asbtr]. Proc Am Soc Clin Oncol 1994;13:A711.Google Scholar
  5. 5.
    Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer 1995; 75 (Suppl) :2000–2003 .Google Scholar
  6. 6.
    Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer [see comments] . DAMA 1992; 267 :2191–2196 .Google Scholar
  7. 7.
    Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T 1/T2 prostatic carcinoma. J Urol 1995;154:1096–1099.PubMedGoogle Scholar
  8. 8.
    Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640–645.PubMedGoogle Scholar
  9. 9.
    Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821–1825.PubMedGoogle Scholar
  10. 10.
    Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32;293–306.PubMedGoogle Scholar
  11. 11.
    Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992;23;47–53.PubMedGoogle Scholar
  12. 12.
    Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16;275–283.PubMedGoogle Scholar
  13. 13.
    Prostate Canvcer Brachytherapy: Clinical and Financial Imperatives for Permanent Implantation, in Oncology Roundtable Annual Meeting. Washington, DC, The Advisory Board Co;15.Google Scholar
  14. 14.
    Sylvester JE, Blasko J, Grimm P. Brachytherapy as Monotherapy, in Prostate Cancer: Principles and Practice (Kantoff P, Carroll PC, D’Amico AV, eds). Philadelphia, Lippincot Williams & Wilkins, 2001; pp. 336–357.Google Scholar
  15. 15.
    Porter AT, Blasko JC, Grimm PD, Reddy SM, Ragde H. Brachytherapy for prostate cancer [see comments]. CA Cancer J Clin 1995;45:165–178.PubMedGoogle Scholar
  16. 16.
    Denning CL. Carcinoma of the prostate seminal vesicles treated with radium. Surg Gynecol Obstet 1922;34:99–118.Google Scholar
  17. 17.
    Scardino P, Carlton C. Combined interstitial and external irradiation for prostatic cancer, in Principles and Management of Urologic Cancer (Javadpour N, ed.). Baltimore, Williams & Wilkins, 983; 392–408.Google Scholar
  18. 18.
    Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol 1972;108:918–920.PubMedGoogle Scholar
  19. 19.
    Blasko JC, Grimm PD, Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993;3:240–249PubMedGoogle Scholar
  20. 20.
    DeLaney TF, Shipley WU, O’Leary MP, Biggs PJ, Prout GR Jr. Preoperative irradiation, lymphadenectomy, and 125iodine implantation for patients with localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:1779–1785.PubMedGoogle Scholar
  21. 21.
    Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991;21:537–547.PubMedGoogle Scholar
  22. 22.
    Giles GM, Brady LW. 125-Iodine implantation after lymphadenectomy in early carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1986;12:2117–2125.PubMedGoogle Scholar
  23. 23.
    Kuban DA, el-Mahdi AM, Schellhammer PF. I-125 interstitial implantation for prostate cancer. What have we learned 10 years later? Cancer 1989;63:2415–2420.PubMedGoogle Scholar
  24. 24.
    Schellhammer PF, Whitmore WF, Kuban DA, El-Mandi AM, Ladaga LE. Morbidity and mortality of local failure after definitive therapy for prostate cancer. J Urol 1989;141:567–571.PubMedGoogle Scholar
  25. 25.
    Morton JD, Harrison LB, Peschel RE. Prostatic cancer therapy: comparison of externalbeam radiation and I-125 seed implantation treatment of stages B and C neoplasms. Radiology 1986;159:249–252.PubMedGoogle Scholar
  26. 26.
    Kovacs G, Galalae R, Loch T, Bertermann H, Kohr P, Schneider R, Kimming B. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol 1999;175(Suppl 2):87–88.PubMedGoogle Scholar
  27. 27.
    Hilaris B, Fuks Z, Nori D, et al.Interstitial irradiation in prostatic cancer: report of 10year results, in Interventional Radiation Therapy Techniques/Brachytherapy (Rolf, ed) Berlin, Springer-Verlag, 1991; p 235.Google Scholar
  28. 28.
    Sylvester J, Blasko JC, Grimm P, Ragde H. Interstitial implantation techniques in prostate cancer. J Surg Oncol 1997;66:65–75.PubMedGoogle Scholar
  29. 29.
    Martinez A, Edmundson GK, Cox RS, Gunderson LL, Howes AE. Combination of external beam irradiation and multiple-site perineal applicator (MUPIT) for treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies. Int J Radiat Oncol Biol Phys 1985;11:391–398.PubMedGoogle Scholar
  30. 30.
    Puthawala A, Syed A, Tansey L. Temporary iridium implant in the management of carcinoma of the prostate. Endocurie Hyper Oncol 1985;1:25–33.Google Scholar
  31. 31.
    Holm HH, Juul N, Pedersen JF, Hansen H, Stroyer I. Transperineal 125-iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283–286.PubMedGoogle Scholar
  32. 32.
    Blasko JC, Radge H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hyperthermia Oncol 1987;3:131–139.Google Scholar
  33. 33.
    Wallner K, Chiu-Tsao ST, Roy J, et al. An improved method for computerized tomography-planned transperineal 125iodine prostate implants. J Urol 1991;146:90–95.PubMedGoogle Scholar
  34. 34.
    Beyer DC, Priestley JB Jr. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys 1997;37:559–563.PubMedGoogle Scholar
  35. 35.
    Grimm PD, Blasko JC, Ragde H. Ultrasound-guided transperineal implantation of Iodine125 and Palladium-103 for the treatment of early-stage prostate cancer: technical concepts in planning, operative technique, and evaluation, in New Techniques in Prostate Surgery, vol 2 (Schellhammer PF,ed). Philadelphia W.B. Saunders Co., 1994; pp. 113–126.Google Scholar
  36. 36.
    Tapen EM, Blasko JC, Grimm PD, Ragde H, Luse R, Clifford S, et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;42:1063–1067.PubMedGoogle Scholar
  37. 37.
    Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:347–353.PubMedGoogle Scholar
  38. 38.
    Arterbery VE, Wallner K, Roy J, Fuks Z. Short-term morbidity from CT-planned transperineal I-125 prostate implants. Int J Radiat Oncol Biol Phys 1993;25:661–667.PubMedGoogle Scholar
  39. 39.
    Priestly JB Jr, Beyer DC. Guided brachytherapy for treatment of confined prostate cancer. Urology 1992;40:27–32.PubMedGoogle Scholar
  40. 40.
    Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three- dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995;32:219–225.PubMedGoogle Scholar
  41. 41.
    D’Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out [see comments] . J Clin Oncol 1996;14:304–315.PubMedGoogle Scholar
  42. 42.
    Dattoli MJ, Wasserman SG, Koval JM, Sorace RA, Cash J, Wallner KE. Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer [abstr]. Int J Radiat Oncol Biol Phys 1995;32(Suppl):251.Google Scholar
  43. 43.
    Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789–799.PubMedGoogle Scholar
  44. 44.
    Blasko JC, Ragde H, Luse RW, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996;23:633–649.PubMedGoogle Scholar
  45. 45.
    Wallner K, Blasko J, Dattoli M. Prostate Brachytherapy Made Complicated. Seattle, Smart Medicine Press, 1997.Google Scholar
  46. 46.
    Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101–108.PubMedGoogle Scholar
  47. 47.
    Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001;50:605–614.PubMedGoogle Scholar
  48. 48.
    Partin AW, Yoo J, Carter HBet al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer [see comments]. J Urol 1993;150110–114.Google Scholar
  49. 49.
    Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] [published erratum appears in JAMA 1997;9,278:118]. JAMA 1997;277:1445–1451.PubMedGoogle Scholar
  50. 50.
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843–848.PubMedGoogle Scholar
  51. 51.
    Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999;85:2630–2637.PubMedGoogle Scholar
  52. 52.
    Sohayda C, Kupelian PA, Ciezki J, Levin HJ, Klein EA. Extent of extracapsular extension: implications for planning for conformal radiotherapy and brachytherapy [abstr] . Int J Radiat Oncol Biol Phys1998;42(Suppl):132.Google Scholar
  53. 53.
    Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993;150:135–141.PubMedGoogle Scholar
  54. 54.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.PubMedGoogle Scholar
  55. 55.
    Blasko JC, Grimm PD, Ragde H. External beam irradiation with palladium-103 implantation for prostate carcinoma. Int J Radiat Oncol Biol Phys 1994;30(Suppl):219.Google Scholar
  56. 56.
    Wallner K. I-125 brachytherapy for early stage prostate cancer: new techniques may achieve better results. Oncology 1991;5:115–126.PubMedGoogle Scholar
  57. 57.
    Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage Tl/T2 prostatic carcinoma. J Clin Oncol 1996;14:449–453.PubMedGoogle Scholar
  58. 58.
    Schellhammer PF, Ladaga LE, El-Mandi A. Histological characteristics of prostatic biopsies after 125iodine implantation. J Urol 1980;123:700–705.PubMedGoogle Scholar
  59. 59.
    Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:31–39.PubMedGoogle Scholar
  60. 60.
    Grimm P, Blasko J, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:31–40.PubMedGoogle Scholar
  61. 61.
    Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T 1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001;51:41–48.PubMedGoogle Scholar
  62. 62.
    Roy JN, Ling CC, Wallner KE, Anderson LL. Determining source strength and source distribution for a transperineal prostate implant. EndocurielHyperthermia Oncol 1996;1235–41.Google Scholar
  63. 63.
    Lederman GS, Cavanagh W, Albert PS, et al. Retrospective stratification of a consecu-tive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 2001;49:1297–3003.PubMedGoogle Scholar
  64. 64.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer [see comments]. J Clin Oncol 2000;18:1164–1172.PubMedGoogle Scholar
  65. 65.
    Grimm P. Clinical results of prostate brachytherapy, in Radiological Society of North America Annual Meeting. Chicago, IL, 1998.Google Scholar
  66. 66.
    Beyer DC, Priestley JB. Biochemical disease-free survival following I-125 prostate implantation [abstr]. Int J Radiat Oncol Biol Phys 1995;32(Suppl):254.Google Scholar
  67. 67.
    Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L. Short-term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys 1994;30:405–409.PubMedGoogle Scholar
  68. 68.
    Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153:1020–1025.PubMedGoogle Scholar
  69. 69.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249–260.PubMedGoogle Scholar
  70. 70.
    Sylvester J.Modern permanent prostate brachytherapy, in American Society of Therapeutic Radiology and Oncology 43rd Annual Meeting. San Francisco, 2001Google Scholar
  71. 71.
    Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 1991;137:113–118.PubMedGoogle Scholar
  72. 72.
    Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166:494–499.PubMedGoogle Scholar
  73. 73.
    Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997;37:565–569.PubMedGoogle Scholar
  74. 74.
    Stone NN, Ratnow ER, Stock RG. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. TechniqueUrol 2000;6:123–127.Google Scholar
  75. 75.
    Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491–500.PubMedGoogle Scholar
  76. 76.
    Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:567–574.PubMedGoogle Scholar
  77. 77.
    Hanks GE, Hanlon AL, Schultheiss TE, et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998;41:501–510.PubMedGoogle Scholar
  78. 78.
    Kupelian PA, Reddy CA, Klein CA. Factors associated with biochemical relaps after either low-dose external beam radiation, high-dose external beam radiation, or radical prostatectomy for localized prostate cancer: 8 year results [abstr] . Int J Radiat Oncol Biol Phys 1999;45(suppl.):219.Google Scholar
  79. 79.
    Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:1011–1018.PubMedGoogle Scholar
  80. 80.
    Prestidge BR, Bice WS, Prete JJ, et al. A dose-volume analysis of permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39(Suppl):289.Google Scholar
  81. 81.
    Ling CC. Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81–87.PubMedGoogle Scholar
  82. 82.
    Nag S, Pak V, Blasko J, et al. Prostate brachytherapy, in Principles and practices of brachytherapy (Nag S, ed). Armonk, Futura Publishing, 1997; pp. 421–440.Google Scholar
  83. 83.
    Hastak SM, Gammelgaard J, Holm HH. Transrectal ultrasonic volume determination of the prostate-a preoperative and postoperative study. J Urol 1982;127:1115–1118.PubMedGoogle Scholar
  84. 84.
    Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826–1830.PubMedGoogle Scholar
  85. 85.
    Prestidge BR, Prete JJ, Buchholz TA, et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998;40:461–465.PubMedGoogle Scholar
  86. 86.
    Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166:876–881.PubMedGoogle Scholar
  87. 87.
    Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823–832.PubMedGoogle Scholar
  88. 88.
    Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000;48 507–512.PubMedGoogle Scholar
  89. 89.
    Nag S, Orton C, Young D, Erickson B. The American brachytherapy society survey of brachytherapy practice for carcinoma of the cervix in the United States. Gynecol Oncol 1999;73:111–118.PubMedGoogle Scholar
  90. 90.
    Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology 1995;45:87–92PubMedGoogle Scholar
  91. 91.
    Grimm PD, Blasko JC, Ragde H, Sylvester J, Clarke D. Does brachytherapy have a role in the treatment of prostate cancer? Hematol Oncol Clin North Am 1996;10:653–673.PubMedGoogle Scholar
  92. 92.
    Ling CC, Li WX, Anderson LL. The relative biological effectiveness of I-125 and Pd-103. Int J Radiat Oncol Biol Phys 1995;32:373–378.PubMedGoogle Scholar
  93. 93.
    Haustermans KM, Hofland I, Van Poppel H, Oyen R, Van de Voorde W, Begg AC, Fowler JF. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:1067–1070.PubMedGoogle Scholar
  94. 94.
    Chu C, Potters L, Ashley R, Waldbaum R, Leibel S. Isotope selection for patients undergoing prostate brachytherapy [abstr]. Int J Radiat Oncol Phys 1998;42(Suppl):134.Google Scholar
  95. 95.
    Wallner K.Personal communication, 2001.Google Scholar
  96. 96.
    Merrick G. Personal Communication, 2001.Google Scholar
  97. 97.
    First Advanced Prostate Brachytherapy Workshop, Seattle Prostate Institute, Seattle, Washington, May 15–16, 1998.Google Scholar
  98. 98.
    Sylvester JE, Grimm PD, Blasko JC. Urethral visualization during transrectal ultrasound guided interstitial implantation for early stage prostate cancer, in Annual Meeting of the Radiologican Society of North America. Chicago, IL, 1998.Google Scholar
  99. 99.
    Wallner K, Roy J, Zelefsky M, Fuks Z, Harrison L. Fluoroscopic visualization of the prostatic urethra to guide transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1994; 29:863–867.Google Scholar
  100. 100.
    Prostate brachytherapy seeds to not expose family members to high levels of radiation. Oncol News Int 2001;10.Google Scholar
  101. 101.
    Gomella LG, Lotfi MA, Reagan GN. Laboratory parameters following contact laser ablation of the prostate for benign prostatic hypertrophy. Technique Urol 1995;1:168–171.Google Scholar
  102. 102.
    Hricak H, Jeffrey RB, Dooms GC, Tanagho EA. Evaluation of prostate size: a comparison of ultrasound and magnetic resonance imaging. Urol Radiol 1987;9:1–8.PubMedGoogle Scholar
  103. 103.
    Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee WR, Coia LR. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment [see comments]. Int J Radiat Oncol Biol Phys 1995;32:325–330.PubMedGoogle Scholar
  104. 104.
    Waterman FM, Yue N, Reisinger S, Dicker A, Corn BW. Effect of edema on the postimplant dosimetry of an I-125 prostate implant: a case study. Int J Radiat Oncol Biol Phys 1997;38:335–339.PubMedGoogle Scholar
  105. 105.
    Prestidge BR, Bice WS, Kiefer EJ, Prete JJ. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy [see comments]. Int J Radiat Oncol Biol Phys 1998;40: 1111–1115.PubMedGoogle Scholar
  106. 106.
    Kaye KW, Olson DJ, Lightner DJ, Payne JT. Improved technique for prostate seed implantation: combined ultrasond and fluoroscopic guidance. J Endourol 1992;6:61–66.Google Scholar
  107. 107.
    Ragde H, Blasko J, Schumacher D, Grimm P. Use of transrectal ultrasound in transperineal I-125 seeding for prostate cancer: methodology. J Endourol 1989;3:209–218.Google Scholar
  108. 108.
    Roy JN, Wallner KE, Chiu-Tsao ST, Anderson LL, Ling CC. CT-based optimized planning for transperineal prostate implant with customized template. Int J Radiat Oncol Biol Phys 1991;21:483–489.PubMedGoogle Scholar
  109. 109.
    Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77:2386–2392.PubMedGoogle Scholar
  110. 110.
    Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapyinduced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001;50:597–604.PubMedGoogle Scholar
  111. 111.
    Blasko JC, Grimm PD, Ragde H. 6 and 7 year results of permanent seed implantation, in Transperineal Brachytherapy: Into the Mainstream. Seattle, WA, Pacific NW Cancer Foundation, 1995.Google Scholar
  112. 112.
    Grier D. Complications of permanent seed implantation. J Brachytherapy Int 2001;17, 205–210Google Scholar
  113. 113.
    Sylvester JE, Grimm P, Blasko J, Meier RM, Heaney CT, Cavanagh W. Transperineal permanent brachytherapy for local recurrence following external beam radiation for earlystage prostate cancer. J Brachyther Int 2001;17:181–188.Google Scholar
  114. 114.
    Sylvester J. Modern Permanent Prostate Brachytherapy, in American Society of Therapeutic Radiology and Oncology. San Francisco, 2001.Google Scholar
  115. 115.
    Blasko J, in Fifth Advanced Prostate Brachytherapy Workshop. Seattle, WA, Seattle Prostate Institute, 2002.Google Scholar
  116. 116.
    Stock RG, Stone NN, DeWyngaert JK. PSA findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate cancer, in Proceedings of the American Radium Society 78th Annual Meeting. Paris, France, 1995; p. 58.Google Scholar
  117. 117.
    Lee WR, Hall MC, McQuellon RP, Case LD, McCullough DL. A prospective quality-oflife study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2001;51:614–623.PubMedGoogle Scholar
  118. 118.
    Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166:947–952.PubMedGoogle Scholar
  119. 119.
    Snyder K, Stock R, Hong S, Lo Y, Stone N. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335–341.PubMedGoogle Scholar
  120. 120.
    Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839–850.PubMedGoogle Scholar
  121. 121.
    Ragde H, Blasko J, Grimm P. Complications of permanent seed implantation, in Transperineal Brachytherapy: Into the Mainstream. Seattle, WA, Pacific NW Cancer Foundation, 1995.Google Scholar
  122. 122.
    Amling C, Bergstralh E, Blute M, Slezak J, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146–1151.PubMedGoogle Scholar
  123. 123.
    Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766–772.PubMedGoogle Scholar
  124. 124.
    Cavanagh W. Seattle Prostate Institute, 2002.Google Scholar
  125. 125.
    Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1–2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997;37:1043–1052.PubMedGoogle Scholar
  126. 126.
    Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol 2001;165:864–866.PubMedGoogle Scholar
  127. 127.
    Steinberg D, Sauvageot J, Piantadosi S, Epstein J. Correlation of prostate needle biopsy and radical prostatectomy gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566–576.PubMedGoogle Scholar
  128. 128.
    Epstein J. Gleason score 2–4 adenocarcinoma of the prostate on needle biopsy. Am J Surg Pathol 2000;24:477–478.PubMedGoogle Scholar
  129. 129.
    Stone NN, Stock RG. Prostate brachytherapy: Treatment strategies. J Urol 1999;162:421–426.PubMedGoogle Scholar
  130. 130.
    Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273–278.PubMedGoogle Scholar
  131. 131.
    Polascik TJ, Pound CR, DeWeese TL, Walsh PC. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis [see comments]. Urology 1998;51:884–889; discussion 889–890.Google Scholar
  132. 132.
    Iczkowski KA, Bostwick DG. The pathologist as optimist: cancer grade deflation in prostatic needle biopsies [editorial]. Am J Surg Pathol 1998;22:1169–1170.PubMedGoogle Scholar
  133. 133.
    Allsbrook WC Jr, Mangold KA, Johnson MH, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 2001;32:74–80.PubMedGoogle Scholar
  134. 134.
    Sylvester J, Blasko J, Grimm P, et al. Neoadjuvant androgen ablation combined with external beam radiation therapy and permanent interstitial brachytherapy boost in localized prostate cancer. Mole Urol 1999;3:231–237.Google Scholar

Copyright information

© Humana Press Inc. Totowa, NJ 2003

Authors and Affiliations

  • John Sylvester
  • John Blasko
  • Peter Grimm

There are no affiliations available

Personalised recommendations